Edsbagge Mikael, Andreasson Ulf, Ambarki Khalid, Wikkelsø Carsten, Eklund Anders, Blennow Kaj, Zetterberg Henrik, Tullberg Mats
Department of Clinical Neuroscience, Hydrocephalus Research Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory,Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
J Alzheimers Dis. 2017;58(3):821-828. doi: 10.3233/JAD-161257.
Neuropathologically, Alzheimer's disease (AD) is characterized by accumulation of a 42 amino acid peptide called amyloid-β (Aβ42) in extracellular senile plaques together with intraneuronal inclusions of hyperphosphorylated tau protein in neurofibrillary tangles and neuronal degeneration. These changes are reflected in the cerebrospinal fluid (CSF), the volumes and production rates of which vary considerably between individuals, by reduced concentration of Aβ42, increased concentration of phosphorylated tau (P-tau) protein, and increased concentration of total tau (T-tau) protein, respectively.
To examine the outstanding question if CSF concentrations of AD associated biomarkers are influenced by variations in CSF volumes, CSF production rate, and intracranial pressure in healthy individuals.
CSF concentrations of Aβ42, P-tau, and T-tau, as well as a number of other AD-related CSF biomarkers were analyzed together with intracranial subarachnoid, ventricular, and spinal CSF volumes, as assessed by magnetic resonance imaging volumetric measurements, and CSF production rate in 19 cognitively normal healthy subjects (mean age 70.6, SD 3.6 years).
Negative correlations were seen between the concentrations of three CSF biomarkers (albumin ratio, Aβ38, and Aβ40), and ventricular CSF volume, but apart from this finding, no significant correlations were observed.
These results speak against inter-individual variations in CSF volume and production rate as important confounds in the AD biomarker research field.
在神经病理学上,阿尔茨海默病(AD)的特征是一种名为β淀粉样蛋白(Aβ42)的42个氨基酸肽在细胞外老年斑中积聚,同时神经原纤维缠结中有超磷酸化tau蛋白的神经元内包涵体以及神经元变性。这些变化反映在脑脊液(CSF)中,其体积和生成速率在个体之间差异很大,分别表现为Aβ42浓度降低、磷酸化tau(P-tau)蛋白浓度升高和总tau(T-tau)蛋白浓度升高。
探讨健康个体中脑脊液体积、脑脊液生成速率和颅内压的变化是否会影响AD相关生物标志物的脑脊液浓度这一突出问题。
通过磁共振成像体积测量评估了19名认知正常的健康受试者(平均年龄70.6岁,标准差3.6岁)的脑脊液中Aβ42、P-tau和T-tau的浓度,以及其他一些与AD相关的脑脊液生物标志物,同时还测量了颅内蛛网膜下腔、脑室和脊髓脑脊液体积以及脑脊液生成速率。
三种脑脊液生物标志物(白蛋白比率、Aβ38和Aβ40)的浓度与脑室脑脊液体积之间呈负相关,但除此之外,未观察到显著相关性。
这些结果表明,脑脊液体积和生成速率的个体差异并非AD生物标志物研究领域的重要混杂因素。